title: Inhibitory effects of etodolac, a selective COX-2 inhibitor, on the occurrence of tumors in colitis-induced tumorigenesis model in rats.
abstract: Ulcerative colitis (UC)-associated neoplasia is one of the complications seen in patients with long-standing UC. Based on many epidemiological studies, colitis is assumed to promote colon tumorigenesis. Tumorigenesis is known to be suppressed in rodents and humans by selective cyclooxygenase-2 inhibitors. However, whether these drugs would serve as protective agents against UC-associated neoplasia remains unclear. Therefore, using a colitis-induced tumorigenesis rat model, we investigated the effects of etodolac, a selective cyclooxygenase-2 inhibitor, on tumorigenesis. The following 4 groups were examined: group A, administered trinitrobenzene sulfonic acid and 1,2-dimethylhydrazine; group B, in addition to the treatment in group A, also received etodolac; group C, administered etodolac alone; and group D, did not receive any agent throughout the study and served as an untreated control. The rats were sacrificed 163 days after the start of experiment, and the number of aberrant crypt foci and tumors in the intestine were counted using a stereoscopic microscope following methylene blue staining. The mean number of aberrant crypt foci was 52.4 in group A, 18.9 in group B, 0 in group C and 0.5 in group D. A total of 9 tumors were observed in group A alone, with none in the remaining groups. The numbers of aberrant crypt foci and tumors in group B were significantly lower than in group A. Etodolac, a selective cyclooxygenase-2 inhibitor, suppresses the occurrence of aberrant crypt foci and tumors in colitis-induced tumorigenesis in rats.
authors.affiliation: Department of Surgical and Molecular Pathology, Dokkyo University School of Medicine, Mibu, Shimotsuga, Tochigi 321-0293, Japan.
authors.forename: Jun
authors.initials: J
authors.lastname: Takeda
authors.forename: Kazuaki
authors.initials: K
authors.lastname: Kitajima
authors.forename: Shigehiko
authors.initials: S
authors.lastname: Fujii
authors.forename: Hideki
authors.initials: H
authors.lastname: Horiuchi
authors.forename: Hiroshige
authors.initials: H
authors.lastname: Hori
authors.forename: Yoko
authors.initials: Y
authors.lastname: Chibana
authors.forename: Takashi
authors.initials: T
authors.lastname: Okuyama
authors.forename: Keiichi
authors.initials: K
authors.lastname: Tominaga
authors.forename: Kazuhito
authors.initials: K
authors.lastname: Ichikawa
authors.forename: Yuko
authors.initials: Y
authors.lastname: Ono
authors.forename: Tadahisa
authors.initials: T
authors.lastname: Teramoto
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Ohkura
authors.forename: Joji
authors.initials: J
authors.lastname: Imura
authors.forename: Motoo
authors.initials: M
authors.lastname: Shinoda
authors.forename: Tsutomu
authors.initials: T
authors.lastname: Chiba
authors.forename: Choitsu
authors.initials: C
authors.lastname: Sakamoto
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Kawamata
authors.forename: Takahiro
authors.initials: T
authors.lastname: Fujimori
mesh_terms: D000818:Animals; D003092:Colitis / Q000150:complications*; D003110:Colonic Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology*; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D004195:Disease Models, Animal; D017308:Etodolac / Q000494:pharmacology* / Q000627:therapeutic use; D007422:Intestines / Q000187:drug effects / Q000473:pathology; D051381:Rats
chemical_list: D016861:Cyclooxygenase Inhibitors; D017308:Etodolac